TARGET-DERM is a unique opportunity to better understand the natural history of atopic dermatitis and other skin diseases and to evaluate different treatment regimens, outcomes and adverse events across a large, diverse patient population. It is our hope that this research can better inform how these conditions are approached and ultimately improve the lives of the millions of people who suffer from them.
Emma Guttman, MD, PhD
Immune-Mediated Inflammatory Skin Conditions (IMISCs), such as atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, and alopecia areata, are skin diseases diagnosed that require substantial financial investment to develop research and appropriate treatments.
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other IMISCs in usual clinical practice, within academic and community real-world centers. The study aims to help assess the safety and effectiveness of current and future therapies. The study is disease-focused, not treatment-specific, allowing for a continuous acquisition of natural history and outcomes data.
The DERM platform was established to bridge the gap in IMISC research by creating a cooperative consortium of principal investigators from academic institutions and community-based sites treating patients with IMISCs. This partnership provides unique opportunities to engage networked physician teams in evidence-based IMISC therapy evaluations and involve these teams in conducting clinical research. Partners can query the longitudinal dataset derived from medical records and patient-reported outcome measures as well as access clinically linked biospecimens to conduct further research analyses.